RNA Clinical Trials Videos

  1. How Is mRNA "Shaking Up" Our Regulatory Interactions & Operations Today? 5/10/2024

    The Advancing RNA Live panelists share several inconsistencies they’ve encountered working with global regulators, as well as on which aspects they’re seeing regulatory agencies applying greater scrutiny in mRNA development today.

  2. Capstan Therapeutics' CEO Laura Shawver On In Vivo Cell Engineering 11/10/2022

    Capstan Therapeutics' CEO, Laura Shawver, Ph.D., talks us through the company's in vivo CAR therapies and what led to the in vivo cell engineering breakthrough that has been decades in the making. Shawver explains the promise of harnessing mRNA and targeted LNP delivery to train a patient’s body to make CAR-T cells in vivo. She also details best practices to garner funding and investment partnership.

  3. Go/No Go Decisions Based On Early Phase Oncology Trials 9/22/2022

    In this webinar, gain insight into the latest regulatory and clinical developments in the field of oncology in China.

  4. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

    mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

  5. A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino 9/11/2024

    Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery.

  6. The Intersection Of RNA, AI, And Synthetic Biology With Shape Therapeutics' Dr. Francois Vigneault 7/18/2023

    Dr. Francois Vigneault, Co-Founder, President, and CEO at Shape Therapeutics joins Cell & Gene: The Podcast's Erin Harris to discuss how RNA technologies are shaping the future of gene therapy. They also discuss AI's role in gene therapy as well as how the CGT sector is benefiting from RNA, AI, and synthetic biology.

  7. Precision ADVANCE: Unravelling The Complexity Of CGTx Development 10/12/2021

    Need help unravelling the complexity of CGTx development? Four experts explain Precision ADVANCE’s unique approach. Spend 50 seconds with Anshul Mangal, Deb Phippard, Megan Liles, and Philip Cyr.

  8. Goldilocks & The 3…CQAs? Finding "Just Right" With LNP Optimization 12/4/2024

    Three LNP experts from Sanofi, Hopewell Therapeutics, and BioNTech collectively discuss how far we’ve come in understanding the structure of our LNPs while also shedding light on the variables that have the greatest potential of causing shifts in our products’ structure/function.

  9. What Have We Learned About Our LNP's Function In Vitro In 2024? 12/4/2024

    BioNTech’s Ben Muir shares a high-level overview of the LNP preclinical research advances that are the most exciting/promising today — while also reminding us of a few important caveats that accompany early-stage research. 

  10. Q&A On LNP Cell-Specific Delivery 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.